Prosecution Insights
Last updated: November 20, 2026

Ernst V Arnold, USPTO Patent Examiner

Listed by the USPTO as ARNOLD, ERNST V

Tech Center 1600 • Art Units: 1600 1613 1614 1616 1617 1626

This examiner grants 48% of resolved cases

Analysis

ARNOLD, ERNST V is assigned to Tech Center 1600 and Art Unit 1600. The record includes 1399 resolved cases, an allowance rate of 48.2%, and a median of 1165 days to allowance. The large case volume gives the outcome rate substantial historical context. The median indicates that prosecution may continue for a significant period before allowance, making timing a central planning issue.

The interview lift is 12.6%, providing a separate measure for evaluating examiner communication. The listed companies are L'Oréal, Cydex Pharmaceuticals Inc., and Fujifilm Holdings Corporation. The listed firms are Greenberg Traurig, LLP (BOS), Sughrue Mion, PLLC, and ArentFox Schiff LLP - New York. These recurring names may assist counsel researching relevant prosecution activity.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

48.2%
Allow Rate
-11.8% vs TC avg
1,484
Total Applications
+12.6%
Interview Lift
1165
Avg Prosecution Days
Based on 1399 resolved cases, 2023–2026

Rejection Statute Breakdown

2.9%
§101 Eligibility
16.0%
§102 Novelty
43.1%
§103 Obviousness
19.8%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18884577 LIPID COMPOSITION Final Rejection FUJIFILM Corporation
19048816 GINGEROL COMPOSITIONS AND RELATED METHODS Final Rejection ThermoLife International, LLC
18205399 Hemostatic Foam Final Rejection STRYKER EUROPEAN OPERATIONS HOLDINGS LLC
18674730 PREPARATION OF PHARMACEUTICAL COMPOSITIONS USING SUPERCYCLE VAPOR PHASE DEPOSITION OF METAL OXIDES Non-Final OA Applied Materials, Inc.
17622585 TRANSFECTION METHOD Final Rejection Takeda Pharmaceutical Company Limited
17831796 Oral Care Products and Methods Final Rejection BASF SE
19016307 PHARMACEUTICAL COMPOSITIONS FOR IMPROVING INTESTINAL BACTERIAL FLORA AND RELATED TREATMENT METHODS Final Rejection Murata Manufacturing Co., Ltd.
18839767 SPONGES BASED ON COLLAGEN-LIKE PROTEINS Final Rejection Evonik Operations GmbH
18842107 OIL-IN-WATER EMULSION COMPOSITION Non-Final OA OTSUKA PHARMACEUTICAL FACTORY, INC.
18993843 ANTIVIRUS COMPOSITE RESIN COMPOSITION WITH EXCELLENT VIRUS INACTIVATION FUNCTION AND COMPOSITE-RESIN-COATED STEEL SHEET USING SAME Non-Final OA POSCO CO., LTD
18679749 HYBRID NAIL COMPOSITION Final Rejection L'ORÉAL
17906514 CONTINUOUS MELT-COATING OF ACTIVE PHARMACEUTICAL INGREDIENTS USING SURFACTANTS FOR DISSOLUTION ENHANCEMENT Final Rejection Rutgers,The State University of New Jersey
18869120 COSMETIC MATERIAL COMPOSITION AND FIBER TREATMENT COMPOSITION FOR HEAD DECORATION PRODUCTS Non-Final OA KAO CORPORATION
18843771 Materials and Methods for Treating Iron Deficiencies and Iron Chlorosis in Plants Non-Final OA Locus Solutions IPCo, LLC
18802979 STABLE CAPSULES WITH FECAL MICROBIOTA OR A CULTURE OF MICROORGANISMS Final Rejection Chr. Hansen A/S
18287604 Thermally Stable Lipid-Nucleic Acid Molecule Formulations Utilising Metal Organic Framework (MOF) Shells Non-Final OA Commonwealth Scientific and Industrial Research Organisation
18631588 CLEVIDIPINE EMULSION FORMULATIONS CONTAINING ANTIMICROBIAL AGENTS Final Rejection CHIESI FARMACEUTICI S.P.A.
17755425 Compositions of Clofazimine, Combinations Comprising Them, Processes for Their Preparation, Uses and Methods of Treatment Comprising Them Final Rejection MannKind Corporation
18810352 LIPID COMPOUND, LIPID NANOPARTICLE COMPRISING SAME AND USE THEREOF Non-Final OA TheMedium Therapeutics Co., Ltd
18690921 COMPOSITIONS OF RAPAMYCIN AND THEIR USE IN THE TREATMENT OF MICROCYSTIC LYMPHATIC MALFORMATION Final Rejection PALVELLA THERAPEUTICS, INC.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Who Appears Before This Examiner

Top companies before this examiner

Law firms appearing most often

Frequently Asked Questions

What is examiner Ernst V Arnold's allowance rate?

48.2% of resolved applications examined by Ernst V Arnold were allowed (1,399 resolved cases), compared with 36.5% across Art Unit 1600 over the last five years.

Does an interview help with examiner Ernst V Arnold?

This examiner's interview lift is +12.6 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.

How long does examiner Ernst V Arnold take to allow a patent?

Applications allowed by Ernst V Arnold took 1,165 days on average from filing to allowance.

Which art unit does examiner Ernst V Arnold work in?

Ernst V Arnold examines applications in Art Unit 1600 in Tech Center 1600 (Biotechnology & Pharmaceuticals).

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month